Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

por Song, Xuyang, Kelley, Robin Kate, Khan, Anis A., Standifer, Nathan, Zhou, Diansong, Lim, KyoungSoo, Krishna, Rajesh, Liu, Lu, Wang, Kun, McCoon, Patricia, Negro, Alejandra, He, Philip, Gibbs, Megan, Kurland, John F., Abou-Alfa, Ghassan K.
Publicado 2023

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

por Wildsmith, Sophie, Li, Weimin, Wu, Song, Stewart, Ross, Morsli, Nassim, Raja, Rajiv, Zhang, Qu, Ye, Jiabu, He, Philip, Shetty, Jagdish, Yovine, Alejandro, Holoweckyj, Nicholas, Real, Katia, Walker, Jill, Wrona, Magdalena, de los Reyes, Melissa, Barker, Craig, Whiteley, Jessica, Haddad, Robert, Licitra, Lisa, Ferris, Robert, Fayette, Jérôme, Zandberg, Dan P., Siu, Lillian L., Mesía, Ricard
Publicado 2023

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

por Kelley, Robin Kate, Sangro, Bruno, Harris, William, Ikeda, Masafumi, Okusaka, Takuji, Kang, Yoon-Koo, Qin, Shukui, Tai, David W.-M., Lim, Ho Yeong, Yau, Thomas, Yong, Wei-Peng, Cheng, Ann-Lii, Gasbarrini, Antonio, Damian, Silvia, Bruix, Jordi, Borad, Mitesh, Bendell, Johanna, Kim, Tae-You, Standifer, Nathan, He, Philip, Makowsky, Mallory, Negro, Alejandra, Kudo, Masatoshi, Abou-Alfa, Ghassan K.
Publicado 2021